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Abstract.  Cell adhesion to extracellular matrix com- 
ponents such as fibronectin has a  complex basis, in- 
volving multiple determinants on the molecule that re- 
act with discrete cell surface macromolecules. Our 
previous results have demonstrated that normal and 
transformed cells adhere and spread on a  33-kD hepa- 
rin binding fragment that originates from the carboxy- 
terminal end of particular isoforms (A-chains) of hu- 
man fibronectin.  This fragment promotes melanoma 
adhesion and spreading  in an arginyl-glycyl-aspartyl- 
serine (RGDS) independent manner,  suggesting that 
cell adhesion to this region of fibronectin is indepen- 
dent of the typical RGD/integrin-mediated binding. 
Two synthetic peptides from this region of fibronectin 
were recently identified that bound [3H]heparin in a 
solid-phase assay and promoted the adhesion and 
spreading of melanoma cells (McCarthy, J.  B., M.  K. 
Chelberg,  D. J.  Mickelson, and  L. T.  Furcht.  1988. 
Biochemistry.  27:1380-1388).  The current studies fur- 
ther define the cell adhesion and heparin binding prop- 
erties of one of these synthetic peptides.  This peptide, 
termed peptide I, has the sequence YEKPGSP- 
PREVVPRPRPGV and represents residues  1906-1924 
of human plasma fibronectin.  In addition to promoting 
RGD-independent melanoma adhesion and spreading 
in a concentration-dependent manner,  this peptide 
significantly inhibited cell adhesion to the 33-kD frag- 
ment or intact fibronectin.  Polyclonal antibodies gener- 
ated against peptide I also significantly inhibited cell 
adhesion to the peptide, to the 33-kD fragment,  but 
had minimal effect on melanoma adhesion to fibronec- 
tin.  Anti-peptide I antibodies also partially inhibited 
[3H]heparin binding to fibronectin,  suggesting that 
peptide I represents a major heparin  binding domain 
on the intact molecule.  The cell adhesion activity of 
another peptide from the 33-kD fragment,  termed CS1 
(Humphries,  M. J., A.  Komoriya, S. K. Akiyama, K. 
Olden,  and K.  M.  Yamada.  1987. J.  Biol.  Chem., 
262:6886-6892) was contrasted with peptide I. 
Whereas both peptides promoted RGD-independent 
cell adhesion,  peptide CS1 failed to bind heparin,  and 
exogenous peptide CS1  failed to inhibit peptide I-medi- 
ated cell adhesion.  The results demonstrate a  role for 
distinct heparin-dependent  and -independent cell adhe- 
sion determinants on the 33-kD fragment,  neither of 
which are related to the RGD-dependent integrin  inter- 
action with fibronectin. 
T 
UMOR cell adhesion  to extracellular  matrix  compo- 
nents is a fundamental  consideration  of invasion and 
metastasis  (Liotta  et  al.,  1983;  McCarthy  et  al., 
1985). Over the last several years, it has been shown that the 
adhesion of normal  and  transformed  cells to extracellular 
matrix proteins such as fibronectin has a complex molecular 
basis.  The recognition  of the arginyl-glycyl-aspartyl-serine 
(RGDS) sequence by cell surface integrin(s)  is the best un- 
derstood mechanism that cells use to adhere to fibronectin 
and other matrix  and plasma proteins (Buck and Horwitz, 
1987; Juliano,  1987; Hynes, 1987; Ruoslahti,  1988). Despite 
the importance of this interaction  to cell adhesion,  there is 
clear evidence indicating  the involvement of other cell sur- 
face macromolecules and other biologically active domains 
on fibronectin. 
We have previously demonstrated that a 33-kD heparin- 
binding fragment,  which originates  from the carboxy-termi- 
nal region of fibronectin A-chains, is active at promoting the 
RGD-independent  adhesion  and spreading  of murine mela- 
noma and  fibrosarcoma cell lines  (McCarthy et al.,  1986, 
1988a,b). This fragment can inhibit experimental metastasis 
when preincubated with tumor cells ex vivo before tail vein 
injection  (McCarthy et al.,  1988b).  Other cell types, such 
as neurons from the developing chicken (Rogers et al., 1987), 
endothelial cells (Visser et al., 1989), and lymphocytes (Liao 
et al.,  1989; Wayner et al.,  1989) also adhere to this frag- 
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to localize a melanoma adhesion-promoting activity on a re- 
gion of this fragment, which excluded the type IIIcs connect- 
ing sequence (McCarthy et al.,  1988a). This approach was 
complemented with the identification of two heparin-binding 
synthetic peptides  that promoted  melanoma  cell  adhesion 
(McCarthy et al., 1988a). The peptides, termed I and 1I, have 
different primary structures (YEKPGSPPREVVPRPRPGV 
and  KNNQKSEPLIGRKKT,  respectively)  yet  they  share 
some common features,  including  a  low (hydrophilic)  hy- 
dropathy index and a positive net charge. Whereas both pep- 
tides bear a net positive charge,  not all positively charged 
peptides produced from matrix proteins (e.g., laminin) will 
promote melanoma cell adhesion  (Charonis  et al.,  1988), 
suggesting that charge alone is not the sole explanation for 
the activity of such peptides.  That the fibronectin peptides 
bind both [3H]heparin and promote cell adhesion suggests a 
role for cell surface heparin-like molecules (i.e., glycosami- 
noglycans  or proteoglycans)  in  promoting  melanoma  cell 
adhesion to this region of fibronectin. 
A synthetic peptide approach has also been used by others 
to identify  an additional  cell adhesion  promoting  domain 
within fibronectin A-chains (Humphries et al.,  1987). Syn- 
thetic peptide CS1 has the primary structure DELPQLVTL- 
PHPNLHGPEILDVPST and is present within the 33-kD hep- 
arin-binding  fragment of human plasma fibronectin (McCarthy 
et al., 1988a). This peptide has been reported to promote cell 
adhesion and spreading and to promote neurite extension by 
dorsal root ganglion neurons (Humphries et al., 1987,  1988; 
Dufour et al.,  1988). Peptide CS1 is located to the carboxy- 
terminal side of both RGDS and the carboxy-terminal hep- 
arin-binding  domain of fibronectin.  Further  evidence sug- 
gests  that  yet  another  cell  adhesion/spreading  domain  is 
located to the amino-terminal  side of the RGDS sequence 
(Obara et al., 1988). While receptors for the heparin-binding 
cell adhesion promoting domains of fibronectin have yet to 
be identified, peptide CS1 has been shown to promote cell 
adhesion through an integrin-dependent mechanism. Anti-/31 
integrin antibodies have been reported to perturb cell adhe- 
sion to peptide CS1 (Dufour et al.,  1988; Humphries et al., 
1988), and recently T lymphocyte adhesion to this region of 
fibronectin has been demonstrated to involve ~in ix4/31 inte- 
grin which is RGD-independent (Wayner et al.,  1989). 
These studies further examined the role for peptide I  in 
melanoma cell adhesion and spreading. The results support 
the contention  that peptide I,  located within  the carboxy- 
terminal heparin binding region of fibronectin, represents a 
major heparin-binding determinant that promotes cell adhe- 
sion  in  an  RGDS-independent  manner.  Furthermore,  the 
adhesion-promoting  activity of this peptide and of peptide 
CS1  could be distinguished  by several criteria,  suggesting 
that the two peptides promote cell adhesion by distinct mech- 
anisms. 
Materials and Methods 
Cell Culture 
The cells used for these studies were the metastatic melanoma cell line 
K1735  M4, originally supplied as a  generous gift from Dr.  I.  J.  Fidler 
(Houston, TX). Cells were passaged in vitro in DMEM containing 10% calf 
serum by methods previously described (McCarthy et al.,  1986,  1988a). 
The metastatic potential of this cell line has been previously confirmed by 
our laboratory (McCarthy et al., 1988b). Care was taken to limit the number 
of in vitro passages to 10 to minimize phenotypic drift. 
Protein and Fragment Isolation 
Human  plasma fibronectin was purified as a  byproduct of Factor VIII 
production by sequential ion-exchange and gelatin affinity chromatography 
as described (McCarthy et al.,  1986,  1988a).  The 33-kD heparin binding 
fragment, which originates from A-chains of fibronectin, was purified from 
tryptic/catbeptic digests of intact fibronectin using sequential gelatin, hepa- 
rin, and antibody affinity columns as described previously (McCarthy et al., 
1988a).  Laminin and type IV  collagen were purified from the murine 
Englebreth-Holm-Swarm tumor as described previously (Herbst et al., 
1988).  The purity of intact proteins and the 33-kD fragment of fibronectin 
was verified by SDS-PAGE and Coomassie brilliant blue staining. 
Peptide Synthesis and Characterization 
Peptides from fibronectin were synthesized at the Microchemical Facility 
of the University of Minnesota by Dr. Robert Wohiheuter using a peptide 
synthesizer (System 990; Beckman Instruments Co., Fullerton, CA). The 
procedures used were based on the Merrifield solid-phase system as de- 
scribed previously (Stewart and Young,  1984).  Lyophilized crude peptides 
were purified by preparative reverse-phase HPLC on a C-18 column, using 
an elntion gradient of 0-60% acetonitrile with 0.1% trifluoracetic acid in 
water.  The purity and composition of the peptides was verified by HPLC 
analysis of hydrolysates prepared by treating the peptides under nitrogen in 
6 N HCI overnight at II0*C. The peptides included heparin binding pap- 
tides  I  and  II  (McCarthy  et  al.,  1988a),  which  have  the  sequences 
YEKPGSPPREVVPRPRPGV and  KNNQKSEPLIGRKKT,  respectively. 
Peptide CS1, which has the sequence DELPQLVTLPHPNLHGPEILDVPST 
(Humphries et al.,  1987) was also synthesized. The sequences shown use 
the single-letter amino acid code (K =  lysine, R =  arginina, H =  histidina, 
E  =  glutamic acid, D  =  aspartic acid, Q  =  glutamine, N  =  asparagine, 
P  =  proline, G  =  glycine, S  =  serine, T  =  threonine, V  =  valine, I  = 
isoleucine, L  =  leucine, Y  =  tyrosine). 
Coupling of  Synthetic Peptides to IgG 
Peptides I and CSI were coupled to normal rabbit IgG as suggested by Hum- 
phries et al. (1987).  However, we used carbodiimide as a coupling reagent, 
based on a procedure described previously (Bauminger and Wilcbek, 1980). 
Briefly,  equal amounts (by weight) of peptide and IgG were solubilized in 
water and mixed with a 10-fold excess (by weight) of l-ethyl-3 (3-dimethyl- 
aminopropyl)-carbodiimide hydrochloride (Sigma Chemical Co., St. Louis, 
MO) dissolved in water.  The sample was then mixed overnight at 4°C on 
a circular rotator.  The coupled peptide was then dialyzed extensively in PBS 
to remove the excess carbodiimide and uncoupled peptide (10,000-D exclu- 
sion; Spectrum Medical Industries, Los Angeles, CA). 
Cell Adhesion Assays 
The cell adhesion assay was essentially the same as described previously 
(Skubitz et al., 1987). Briefly, purified fibronectin, 33-kD heparin-binding 
fragment of fibronectin, or the various synthetic peptides were diluted to 
various concentrations in PBS, and 50-#I aliquots were dispensed in tripli- 
cate to microtiter wells (Immulon  l;  Dynatech Laboratories,  Chantilly, 
VA). The wells were dried overnight in a 29°C oven, and nonspecific sites 
on the plastic were then blocked for 3 h by treating the wells with 200/zl 
of PBS containing 2 mg/ml fatty acid-free BSA (Miles Laboratories, Elk- 
hart, IN). Alternatively, purified fibronectin, normal rabbit IgG, or the pep- 
tides that were coupled to normal rabbit IgG were diluted in PBS and I00-/~I 
aliquots were dispensed in triplicate into microtiter wells. The wells were 
incubated at room temperature for 60 rain as described (Yamada and Ken- 
nedy, 1984; Humphries et al., 1987),  nonadsorbed proteins were removed, 
and the wells were incubated with 2 mg/ml BSA in PBS for 3 h. 
Subconfluent K1735 M4 melanoma cells, which had been radiolabeled 
overnight with tritiated thymidine, were released from culture flasks by tryp- 
sin/EDTA, washed, and adjusted to a concentration of 5  x  104 cells per ml 
of DME containing 0.15 mM Hepes (pH 7.2) and 2 mg/ml BSA. The cells 
were dispensed in a volume of 100/~1 to the microtiter wells. Depending 
on the experiment, the incubation time for the assay ranged from 30 min 
to 2 h. The assays were terminated by aspirating loosely bound and unbound 
cells from the wells, washing the wells three times, and solubilizing the 
bound cells in 0.5 N NaOH containing 1% SDS. Bound radioactivity, deter- 
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Co.), was used to calculate the percentage of ceUs adherent in each sample. 
In parallel experiments, adherent cells were fixed with 2% glutaraldehyde 
in PBS and photographed on a Nikon Diaphot inverted-phase microscope. 
Cell adhesion was inhibited both by synthetic peptides and polyclonal an- 
tibodies raised against the synthetic peptides. To test for inhibition of cell 
adhesion by synthetic peptides, cells were first preincubated in various con- 
centrations of synthetic peptides for 30 min before the cell adhesion assay. 
The exogenous peptides were included in the adhesion assay for the duration 
of the experiment. When antibodies were tested for inhibition of cell adhe- 
sion, various concentrations of purified immunoglobulins generated against 
peptide I or normal rabbit immunoglobulin were diluted in the cell adhesion 
medium and preincubated on the plates for 30 rain before the addition of 
cells. As was the case for the peptide inhibition experiments, the antibodies 
remained in the cell adhesion assay for the duration of  the experiment. After 
the 30-min preincubation, the cells were incubated in the protein-coated 
wells for 30 min. Nonadherent cells were then aspirated off, the wells were 
washed, and bound cells were quantitated as described above. 
Purification of Commercial pH]Heparin 
Before  use  in  the  [3H]heparin  solid-phase binding  assays,  commercial 
[3H]heparin (0.03 mCi/mg sp act; ICN Immunobiologicals, Lisle, IL) was 
first purified to create a sample that was homogeneous by size and charge. 
The [3H]heparin was first applied to a Sephadex G-50 column (0.5  ×  25 cm) 
equilibrated in 0.1 M ammonium formate. The radioactivity in the void vol- 
ume (Vo) of this column was concentrated by lyophilization  and resuspended 
in the starting buffer (DEAE buffer) for the (DEAE) ion exchange column: 
0.05 M Tris-HCI, pH 7.0, containing 6 M urea, 0.1 M NaCl, and 0.2% CHAPS. 
[3H]Heparin was purified by HPLC (model 110 A; Beckman Instruments 
Co.) using a 7.5  x  75 mm TSK DEAE 5PW anion-exchange column (Bio- 
Rad Laboratories, Richmond, CA). The sample was applied at a flow rate 
of I ml/min, and the column was washed with 20 column volumes of DEAE- 
buffer.  [3H]Heparin was eluted with a linear salt gradient from 0.1  M to 
0.8 M NaCl over 45 rain (a rate of  0.015 M/min). The radioactive peak from 
this column was dialyzed against water, concentrated by lyophilization, and 
resuspended in 0.5 M sodium acetate buffer containing 0.2% CHAPS. The 
hydrodynamic size of [3H]heparin was estimated by gel filtration on 0.9  × 
110 cm Sepharose CL-6B columns. The columns were equilibrated and 
eluted with 0.5 M sodium acetate containing 0.2 % CHAPS, pH 7.0, at a flow 
rate of 3 to 4 ml/h (Klein et al., 1986). Fractions of 1.0-1.2 ml were collected 
with a 95 % recovery of radioactivity. Rat chondrosarcoma chondroitin sul- 
fate proteoglycan (Oegema et al., 1975) associated with 4% hyaluronic acid, 
and gtucuronolactone, were used to mark the column void (Vo) and total 
(V0 volumes, respectively. [3H]Heparin chain size was estimated based on 
the previous data of Wasteson (1971).  The concentration of the purified 
[3H]heparin  was determined by uronic acid analysis as described previously 
(Bitter and Muir,  1964). 
Solid-Phase [3H]Heparin Binding Assay 
The ability of the various ligands to bind purified [3H]heparin was assessed 
using a solid-phase binding assay that used either Immulon 1 plates (Skubitz 
et al.,  1988) or Immulon C plates (McCarthy et al.,  1988a)  as a support. 
In either case, the substrata were prepared by drying the various ligands onto 
the surface of the wells as for the cell adhesion assays. The plates were then 
blocked with PBS/BSA, and purified [3H]heparin  was added to the wells 
in PBS/BSA. The plates were incubated for 2 h at 370C, at which time they 
were washed 5 times with PBS to remove the unbound [3H]heparin. The 
bound [3H]heparin  was solubilized with 0.5 N NaOH containing 1% SDS, 
and the radioactivity in each sample was quantitated as described above. 
In certain experiments, unlabeled heparin (molecular mass 15 kD, Sigma 
Chemical Co.), dextran sulfate (molecularmass 8 kD, Sigma Chemical Co.) 
or chondroitin--4  sulfate glycosaminoglycans from the rat Swarm chondro- 
sarcoma (Oegema et al., 1975; molecular mass 20 kD, generously supplied 
by Dr.  T.  R.  Oegema) were used in competition assays for [3H]heparin 
binding to the various ligands. For these experiments, various concentra- 
tions of competitor were mixed in PBS/BSA with subsaturating levels of 
[3Hlheparin before addition to the assay,  and the assay performed as de- 
scribed above. 
Purified immunoglobulin generated against peptide I was also tested for 
the ability to inhibit [3H]heparin binding to intact fibronectin. For these as- 
says, various concentrations of purified anti-peptide I immunoglobulin or 
normal rabbit immunoglobulin were diluted in PBS/BSA and incubated on 
fibronectin coated plates at 37°C for 30 min before the assay. A subsaturat- 
ing level of [3H]heparin  was then added to the wells, incubated, and quanti- 
rated as described above. 
Generation and Purification of  Polyclonal Antibodies 
against Peptide I 
Polyclonal antibodies were generated against heparin binding peptide I cou- 
pled to keyhole limpet hemocyanin (KLW, Sigma Chemical Co.) using 
carbodiimide as a coiJpling reagent, as described above for coupling to nor- 
mal rabbit IgG.  However, after the coupling reaction, the coupled peptide 
was dialyzed in Spectrapore 6 tubing (Spectrum Medical Industries) with 
an 1,000-D exclusion so that only the excess carbodiimide was removed and 
any uncoupled peptide would remain in the tubing. This mixture was then 
concentrated in Aquacide II (Calbiochem-Behring Corp., La Jolla, CA) to 
a final concentration of 10 mg/ml, and aliquots were stored at -70°C. The 
coupling of the peptide to KLH was verified by the use of radioiodinated 
peptide in a parallel reaction mixture. 
The coupled mixture was then used to immunize New Zealand White 
Rabbits. Immunization was performed by mixing an equal volume of pep- 
tide/KLH conjugate with CFA and injecting this mixture into multiple sites 
on the shaved backs of the rabbits ('~2 mg of conjugate/rabbit). Subsequent 
biweekly boosts in incomplete Freund's adjuvant were injected i. m. into 
the hind legs of rabbits. Sera were collected 7-10 d after the sixth immuniza- 
tion, and tested by ELISA for reactivity against uncoupled peptide I and var- 
ious other ligands. 
IgG was purified from pooled immune sera by precipitation with a final 
concentration of 45 % ammonium sulfate overnight at 4°C. The precipitate 
was pelleted by centrifugation, resolubilized, and dialyzed against 0.035 M 
NaCl in 0.025  M Tris,  pH 8.2. The IgG was purified over a DEAE anion 
exchange column as described previously (Skubitz et al., 1988).  Purity of 
the IgG was determined by SDS-PAGE and Coomassie brilliant blue stain- 
ing of the gel. Retained immunoreactivity of the purified IgG was verified 
by ELISA. 
ELISA plates (either Immulon I or C) were prepared as for the cell adhe- 
sion assays by drying 1 #g/well oftbe various ligands onto the plates, except 
Vollers buffer was used to dilute the ligands (Smith and Furcht, 1982).  The 
plates were then blocked by incubating the wells for 2 h at room temperature 
with PBS containing 2 mg/ml of ovalbumin (PBS/OA). Various concentra- 
tions of purified IgG were diluted in PBS containing 0.05%  Tween 20 and 
0.36 M NaCl (PBS/Tween) and incubated on the plates for I h at room tem- 
perature on a rotating platform. The plates were washed three times with 
PBS/Tween and  incubated an  additional  hour  with a  1:500  dilution of 
peroxidase-conjugated  goat anti-rabbit immunoglobulin (Cappel Laborato- 
ries, Malvern, PA). The plates were washed extensively with PBS/Tween 
and  developed  with  the  subsequent  addition  of 0.4  mg/ml  of ortho- 
phenylene diamine containing 0,012%  H=,Oz in 0.1  M  sodium phosphate 
and 24 mM citric acid. The reaction was terminated by the addition of 2.5 
M  H2SO,, and the  intensity at  490  nm determined using an automatic 
microplate reader (model EL311;  Bio-Tek Instruments, Burlington, VT). 
Results 
Peptides I and CS1 Promote RGD-independent 
Melanoma Cell Adhesion by Distinct Mechanisms 
Synthetic peptides I and CS1 are clearly distinct in terms of 
primary structure, hydropathy profiles, and charge (Fig. 1). 
Peptide I, which is in type III repeat #14 of human plasma 
fibronectin (Fig.  1, Kornbliht et al., 1985),  represents resi- 
dues 1906-1924, and would be predicted to occur in all iso- 
forms of  fibronectin identified to date (Hynes, 1985). Peptide 
CS1 represents residues 1961-1985 and occurs only on a sub- 
set of human plasma fibronectin molecules (Kornbliht et al., 
1985). The hydropathy values, which were calculated by the 
method of Kyte and Doolittle (1982),  were determined by 
stepwise averaging across a window of  6 residues. According 
to this method, the more hydrophobic regions of  the peptides 
correspond to the more positive numerical values.  Overall, 
1. Abbreviations used in this paper: CS, chondroitin-4 sulfate; KLH, key- 
hole limpet hemocyanin; OA, ovalbumin, 
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Figure 2. Adhesion of melanoma cells to increasing concentrations 
of synthetic peptides. Cells were radiolabeled and incubated for 2 h 
at 37°C in microtiter wells coated with various concentrations  of 
fibronectin (e), peptide I (zx), peptide CS1 (A), or BSA (t3) as de- 
scribed in Materials and Methods. Each value represents the mean 
of three separate determinations,  and the SEM was <5 % in each 
case. Three separate experiments gave similar results. 
peptide CS1 is significantly more hydrophobic than peptide 
I (total net hydropathy indices of -9.9 and  -24.3,  respec- 
tively), with two hydrophobic regions distributed on either 
side of a slightly hydrophilic region.  In contrast, peptide I 
is  amphipathic,  containing  two  extremely hydrophilic  re- 
gions which surround a relatively hydrophobic central por- 
tion of the peptide. Peptide CS1 also carries a net negative 
charge (-4) at neutral pH, in contrast to peptide I which is 
cationic in nature (+2 net charge). 
Uncoupled peptides I and CS1, adsorbed directly to plates, 
promoted melanoma cell adhesion in a concentration-depen- 
dent manner (Fig. 2). The maximum level of adhesion (~35 % 
of input cells) observed on peptide I (2/,g/well) was *60% 
of that observed on intact fibronectin, and was virtually equiva- 
lent to cell adhesion levels on peptide CS1.  Similar results 
were  obtained  when  substrata  were  coated  with  peptides 
which had been coupled to IgG (data not shown). 
Melanoma cell spreading also occurred on substrata coat- 
ed with peptide I, regardless of whether or not the peptide 
had been coupled to IgG (compare Fig. 3, a and b); however, 
the rate of spreading on peptide I was somewhat slower than 
that observed on intact fibronectin (not shown). By contrast, 
the ability of cells to spread on substrata coated with peptide 
CS1  was directly dependent on whether or not the peptide 
had been coupled to IgG before coating.  Substrata coated 
with peptide CS1 coupled to IgG (Fig. 3 c) spread to the same 
extent as cells adherent on peptide I-coated substrata or sub- 
strata  coated  with  intact  fibronectin  (Fig.  3  e).  However, 
when substrata were coated with peptide CS1  that had not 
been coupled, very few cells exhibited a spread morphology 
(Fig. 3 d), despite the fact that such substrata could support 
the same level of cell adhesion as peptide 1-coated substrata 
(Fig.  2).  Virtually no adhesion and spreading of cells oc- 
curred on substrata coated with sham coupled IgG (Fig. 3f) 
or BSA (not shown). 
Our previous results  (McCarthy et al.,  1986,  1988a)  as 
well as the results of others (Wayner et al.,  1989) demon- 
strated that cell adhesion to the 33-kD fragment of fibronec- 
tin  is  independent  of the  RGDS  cell  adhesion  sequence. 
Therefore, the effect of exogenous GRGDSP on melanoma 
cell adhesion to peptides I and CS1  was examined (Fig. 4). 
In agreement with our previous results, exogenous GRGDSP 
was virtually ineffective at inhibiting cell adhesion to the 33- 
kD fragment of fibronectin.  However, GRGDSP was effec- 
tive at inhibiting melanoma cell adhesion to intact fibronec- 
tin, with a maximum level of 50% inhibition observed in the 
presence of 600/*g/ml GRGDSP. Importantly, cell adhesion 
to  peptides  I  and  CS1  was  unaffected  by  the  addition  of 
GRGDSP, even at concentrations which maximally inhibited 
cell adhesion to intact fibronectin (Fig. 4). These results in- 
dicate that the adhesion determinants within both synthetic 
peptides constitute major RGDS-independent cell adhesion 
sites within the 33-kD fragment of fibronectin. As controls 
in this study, GRGDSP was observed to have no effect on cell 
adhesion to laminin- or type IV collagen-coated substrata 
(data not shown). 
Exogenous peptide I inhibited cell adhesion on substrata 
coated with fibronectin, peptide I, or the 33-kD fragment in 
a concentration-dependent manner (Fig. 5 A). The inhibition 
profiles on all three substrata were remarkably similar. How- 
ever, the maximum level of inhibition on peptide I ('~70%) 
was greater than the maximum inhibition observed on either 
the  33-kD  fragment  or  intact  fibronectin  (~50%).  CS1- 
mediated cell adhesion,  in contrast, was totally resistant to 
competition with peptide I, even at a concentration of 600 
/*g/ml of exogenous peptide I. Exogenous peptide I also had 
no effect on melanoma cell adhesion to laminin or type IV 
collagen (data not shown). 
Exogenous  peptide  CS1  inhibited  cell  adhesion  to  sub- 
strata coated with  intact fibronectin,  the 33-kD  fragment, 
and peptide CS1 itself (Fig. 5 B). The inhibition profiles on 
substrata coated with intact fibronectin and the 33-kD frag- 
ment  were  similar,  with  maximum levels of inhibition  at 
,x,40%.  Adhesion to peptide CS1  was most sensitive to the 
Figure 1. Location of synthetic peptides within intact fibronectin and hydropathy profiles of peptides I and CSI. Shown is a schematic dia- 
gram depicting the location of the 33-kD carboxy-terminal heparin binding fragment within fibronectin and the two synthetic heparin bind- 
ing peptides (peptides I and II) as well as peptide CS1. In contrast to peptides I and II, which are present within a type Ill homology common 
to all isoforms of fibronectin, peptide CSI is restricted to isoforms of human plasma fibronectin that contain the type IIIcs region (A-chains). 
The amino terminal end and the carboxy-terminal limit of the 33-kD fragment is based on previous sequence data (McCarthy,  1988a). 
Selected biological domains,  indicated by italicized, underlined  roman numerals at the top of the figure, are based on the nomenclature 
of Furcht (1981). (I) Weak heparin binding; (H) collagen binding (noncovalent); (III) free sulfhydryl; (IV) RGD-mediated cell adhesion; 
(V) carboxy-terminal strong heparin binding and cell adhesion;  (VI) free sulfhydryl. Approximate locations of tryptic (T) and cathepsin 
D (C) sites on intact fibronectin are shown. The sequences and hydropathy profiles for peptides I and CS1 are shown in the lower portion 
of the figure. The hydropathy profiles are calculated across a six-residue window and are based on the values of Kyte and Doolittle (1982). 
According to this method,  the more positive values reflect increasingly hydrophobic character. 
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coated with synthetic peptides. Peptides I (a) and CS 1 
(c) were coupled to IgG as described in Materials and 
Methods and diluted to a  final concentration of 500 
#g/ml IgG. Wells were then coated with 100/zl of pep- 
tide:IgG conjugate or IgG alone  (f).  Alternatively, 
wells were coated with  1 #g of uncoupled peptide I 
(b), CS 1 (d), or intact fibmnectin (e). Cells were then 
incubated for 2 h at 37°C in these microtiter wells and 
photographed as described in Materials and Methods. 
Bar in  f, 45 #m. Two separate experiments gave simi- 
lar results. 
effects of soluble peptide CS1 (70% maximum). Importantly, 
peptide I-mediated cell adhesion  was totally resistant to the 
effects of soluble peptide CS1 at all concentrations.  Cell via- 
bility, as assessed by trypan blue dye exclusion after a  1-h in- 
cubation  in peptides,  was  >90%  in all of these assays. 
Polyclonal lgG against Peptide I Specifically Inhibits 
Peptide 1-mediated Melanoma Cell Adhesion 
Polyclonal antibodies were generated in rabbits against pep- 
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Figure 4.  Peptide  I- and  peptide CSl-mediated  cell  adhesion  is 
RGDS-independent. Cells were preincubated in the indicated con- 
centrations of the hexapeptide GRGDSP for 30 min at 37°C  and 
then added to wells coated with 1/~g fibronectin (I), or 2/zg of 33 
kD fragment (o), peptide I (A), or peptide CSI (A). The assay was 
terminated 30 rain later as described in Materials and Methods and 
the percentage of adherent cells was determined. The percent inhi- 
bition of cell adhesion was quantitated as: (1 minus [the number of 
cells bound in the presence of the inhibitor divided by the number 
of cells bound in the absence of the inhibitor]) multiplied by 100. 
Each value represents the mean of three separate determinations, 
and the SEM was <5 % in each case. Three separate experiments 
gave similar results. 
tide I coupled to KLH. Immune sera were collected and the 
purified  IgG  screened  by  ELISA  for  immunoreactivity 
against various ligands. Anti-peptide I IgG reacted very well 
with  intact  fibronectin,  the  33-kD  fragment,  and  peptide  I 
(Fig. 6); however, as would be expected, the extent of reactiv- 
ity was much greater towards peptide I than towards the 33- 
kD  fragment  or  intact  fibronectin.  This  IgG  was  quite 
specific because it did not react by ELISA against substrata 
coated with ovalbumin, peptide CSI, or fibronectin peptide 
II (see Fig.  1),  which also binds  [3H]heparin  and promotes 
melanoma cell adhesion (McCarthy et al.,  1988a).  In addi- 
tion, the anti-peptide I IgG did not react with laminin, type 
IV collagen,  or BSA  (not shown). 
The effect of anti-peptide I IgG on cell adhesion to various 
ligands was next determined (Fig.  7).  Increasing concentra- 
tions of IgG were extremely effective at inhibiting melanoma 
cell adhesion to the 33-kD  fragment,  with a  highly  signifi- 
cant (70 %) inhibition observed in the presence of 500 ttg/ml 
of anti-peptide  I  IgG. This IgG was even more effective at 
inhibiting  cell adhesion  to substrata coated with  peptide  I, 
with a  virtually complete (95 %) inhibition  observed at the 
highest concentration of IgG. In contrast, anti-peptide I IgG 
was minimally effective (20-25 %) at inhibiting adhesion to 
intact fibronectin, which would be expected since cells should 
be  able  to  adhere  to  RGD-related  and  other  adhesion  se- 
quences within fibronectin not recognized by the antibodies. 
Anti-peptide I IgG had no effect on cell adhesion to laminin, 
peptide CS1, or peptide II (not shown). Normal rabbit immu- 
noglobulin  had no effect on melanoma cell adhesion to any 
of the  substrata tested  (data not  shown). 
Peptide I (But Not CS1) Represents a Major Heparin- 
binding Determinant on Intact Fibronectin 
The ability of peptides I  and CS1  to bind  [3H]heparin were 
compared  using  a  solid-phase  binding  assay  in  which  the 
peptides were bound to the substrata. Before use in these as- 
says, commercial  [3H]heparin  was first purified to obtain a 
fraction that was relatively homogenous  in size and charge 
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Figure 5. Effects of exogenous peptide  I and peptide CS1 on mela- 
noma cell adhesion. Radiolabeled  cells  were preincubated  for 30 
min in increasing concentration of(A) peptide I or (B) peptide CSI, 
then added to wells coated with 1 #g of fibronectin  (=), 2 #g 33- 
kD fragment (o), peptide I (zx), or peptide CSI (&). After a 30-min 
incubation, the nonadherent cells were aspirated  off and the wells 
were washed three times. Adherent cells were quantitated  in a scin- 
tillation counter. The percent inhibition of  cell adhesion was quanti- 
tated as: (1 minus [the number of cells bound in the presence of the 
inhibitor  divided by the number of cells  bound in the absence of 
the inhibitor])  multiplied  by 100. Each value represents  the mean 
of three separate determinations,  and the SEM was <10%  in each 
case. 
characteristics.  The  Vo fractions of a  Sephadex G-50 chro- 
matographic separation of commercial  [3H]heparin (Fig.  8 
A) were pooled, applied to an HPLC-DEAE anion exchange 
column and eluted as a single, sharp peak from this column 
at a salt concentration of 0.56 M NaCI (Fig. 8 B). This radio- 
active peak was pooled, concentrated, and applied to an ana- 
lytical Sepharose CL-6B column from which it eluted at K,v 
0.68 (Fig. 8 C). The procedure yielded pH]heparin with an 
estimated molecular weight of '~8 kD (according to the data 
of Wasteson,  1977) and a  specific activity of 0.08 mCi/mg 
uronic acid. 
Purified [3H]heparin bound in a concentration dependent 
manner to substrata coated with fibronectin, the 33-kD frag- 
ment,  or peptide I  (Fig.  9).  The binding of pH]heparin to 
each of these ligands was specific as a  100-fold excess of un- 
labeled  heparin  completely inhibited  binding.  In contrast, 
substrata coated with 5 #g/well of peptide CS1 were totally 
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Figure 6. Reactivity of purified IgG raised against peptide I-KLH. 
Plates  were coated with  1 #g of fibronectin  (n), the 33-kD frag- 
ment (O), peptides I (zx), II (e), CSI (A), or OA (n). Purified IgG 
from rabbits  immunized with peptide  I coupled to KLH was then 
added to the wells at the indicated concentrations.  The ELISA was 
then performed as described in Materials  and Methods and absor- 
bance readings at 490 nm were taken.  The values shown represent 
the average of triplicate wells with background readings using nor- 
mal rabbit IgG subtracted.  Four experiments  gave similar  results. 
ineffective at binding [3H]heparin, despite the fact that such 
substrata could promote melanoma cell adhesion. Increasing 
the coating concentration of peptide CS1 to levels as high as 
10  #g/well  failed  to  promote  the  binding  of [3H]heparin 
(data not shown). 
The effect of various salt concentrations on the [3H]hepa- 
rin binding of fibronectin, the 33-kD fragment, and peptide 
I was compared (Table I). At physiological salt concentrations 
(0.15  M), each of the three ligands bound [3H]heparin to es- 
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Figure 7. Effect ofanti-peptide I antibodies on melanoma cell adhe- 
sion to intact fibronectin,  33 kD fragment, and peptide I. Radiola- 
beled  cells were incubated  for 30 min at 37°C in microtiter wells 
in the presence of increasing  concentrations of purified  IgG from 
rabbits  immunized  with  peptide  I as described in Materials  and 
Methods.  The wells were coated with l#g of fibronectin  (=), 2 #g 
of 33-kD fragment (o), or peptide I (,x). The percent inhibition  of 
cell  adhesion was quantitated  as:  (1  minus [the number of cells 
bound in the presence of  the inhibitor divided by the number ofceUs 
bound in the absence of the inhibitor]) multiplied by 100. Inhibition 
of cell adhesion in the presence of normal rabbit IgG was then sub- 
tracted at the corresponding IgG concentration. Each value repre- 
sents the mean of three separate determinations,  and the SEM was 
<5 % in each case. Three separate experiments  gave similar results. 
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Figure 8.  Purification  of commercial [3H]heparin.  (A) Commer- 
cial [3H]heparin was applied  to and eluted  from a Sephadex G-50 
column as described in Materials  and Methods.  (B) The Vo frac- 
tions (1.36 ml/fraction)  were pooled as indicated by the bar, concen- 
trated,  and applied to an HPLC DEAE column equilibrated  in 0.05 
M  Tris-HCL, pH 7.0, containing 6 M  urea,  0.1  M NaCI, 0.2% 
CHAPS. The HPLC-DEAE column was eluted with the indicated 
gradient of NaC1 (¢) and the radioactivity  of each 1.0-ml fraction 
determined ([]). (C) The entire peak comprising fractions indicat- 
ed by the bar was pooled, concentrated, and applied to an analytical 
Sepharose  CL-6B column equilibrated  in 0.5  M  sodium acetate 
containing 0.2% CHAPS. The peak fractions were pooled as indi- 
cated by the bar and used  in the [3H]heparin binding  assays. 
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Figure 9.  Binding of [3H]heparin to substrata coated with various 
ligands. Substrata were coated with 4 #g of intact fibronectin (B), 
10/~g of 33-kD fragment (o), 5 #g of peptides  I (zx) or CSI (&), 
or 200/zg of BSA (D) as described in Materials  and Methods.  The 
wells were then blocked with PBS/BSA,  incubated  for 2 h in the 
presence of the indicated  concentrations of purified  [3H]heparin, 
and the amount of bound [3H]heparin determined.  The binding of 
[aH]heparin  in  the  presence  of a  100-fold  excess  of unlabeled 
heparin  was  at  background  levels  of radioactivity.  Each  value 
represents the mean of three separate determinations,  and the SEM 
was <10% of the mean values  in each case. 
sentially the same extent. The capacity of fibronectin to bind 
[3H]heparin was increased approximately twofold when the 
binding was performed  in low  (0.05  M)  salt;  however,  no 
such increase was observed for the 33-kD fragment or peptide 
I. This is what would be expected if the amino terminal weak 
heparin binding domain of fibronectin  (Smith and Furcht, 
1982; McCarthy et al.,  1986; see Fig. 1, domain I) exhibited 
activity at this lower salt concentration.  Increasing the salt 
concentration above 0.15  M  inhibited  the binding of [3H]- 
heparin to essentially the same extent on all three substrata. 
Minimal [aH]heparin binding to each of these three ligands 
was observed in the presence of 0.25  M  NaCI, with essen- 
tially  background binding  observed  at  salt  concentrations 
higher than 0.25  M  NaCI. 
The ability of related polysaccharides to inhibit the bind- 
ing of [3H]heparin  to  intact  fibronectin  and  peptide  I  was 
Table I. Effect of Salt on the Binding of FH]Heparin 
to Fibronectin,  33-kD Fragment,  or Peptide I 
Heparin bound (ng)$ 
Substratum*  0.05  M  0.15  M  0.25  M  0.35  M 
Intact fibronectin  6.3  3.7  0.3  0.2 
33-kD fragment  3.7  3.0  0.6  0.3 
Peptide I  3.4  3.0  0.7  0.2 
BSA  0.4  0.7  0.3  0.2 
* lmmulon  I-coated substrata were prepared by drying down 4  ttg of intact 
fibronectin,  or peptide  I, 200 ttg of BSA, and  10 tzg of 33-kD  fragment as 
described in Materials and Methods. 
$ The effect  of the  indicated  salt concentrations on the binding  of purified 
[3H]heparin  to each substratum was determined. The assay was performed us- 
ing binding buffers that contained the indicated  concentrations of NaCI, and 
each condition was washed with the same concentration of salt used in the assay 
before the determination of the bound [3H]heparin.  The bound radioactivity at 
the end of the assay was solubilized and determined as described and used to 
calculate  the amount of heparin bound to the various substrata. Each well con- 
tained ,',,50 ng of heparin at the beginning of the assay. Values represent the 
means of triplicate  determinations, with the SEs of the means <10%  of mean 
values in all  cases. 
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Figure  10.  Inhibition of [3H]heparin binding to intact fibronectin 
and peptide I by sulfated polysaccharides. Substrata coated with in- 
tact fibronectin (A) or peptide I (B) were prepared as described in 
Materials  and  Methods.  Subsaturating  levels of [3H]heparin (50 
ng/well) were mixed with the indicated concentrations of unlabeled 
heparin (D), dextran sulfate (<>), or chondroitin sulfate (e) and in- 
cubated in the wells for 2 h. The wells were then washed and the 
amount of bound [3H]heparin was determined.  Each value repre- 
sents the mean of three separate determinations, and the SEM was 
<10%  in each case. 
also compared (Fig.  10).  Unlabeled heparin was most effec- 
tive at inhibiting  [3H]heparin binding to either substratum, 
producing a 50%  inhibition at between  10  -9 M  (peptide I) 
and  10  -s M  (fibronectin) competing heparin.  Dextran sul- 
fate was an order of magnitude  less effective at inhibiting 
50% of the binding of [3H]heparin to either substratum. At 
high concentrations, however, dextran sulfate could virtually 
eliminate heparin binding to either ligand,  suggesting that 
high concentrations of dextran sulfate could nonspecifically 
inhibit [3H]heparin binding on the basis of charge.  In con- 
trast, less charged chondroitin-4 sulfate glycosaminoglycans 
were virtually ineffective at inhibiting the binding of [3HI- 
heparin to peptide I or intact fibronectin, even at micromolar 
concentrations. 
Finally, the ability of anti-peptide I IgG to inhibit the bind- 
ing of [3H]hepadn to intact fibronectin was examined (Fig. 
11). This IgG inhibited the binding of [3H]heparin to intact 
fibronectin, in a concentration-dependent fashion. The high- 
est concentration of IgG tested (500/zg/ml) inhibited '~60% 
of the [3H]heparin binding to intact fibronectin. In contrast, 
normal rabbit immunoglobulin was much less effective at in- 
hibiting  [3H]heparin  (19%  inhibition  at  500  /~g/ml,  not 
shown). 
Discussion 
Our previous results were the initial ones that demonstrated 
that fibronectin contains RGDS-dependent and independent 
adhesion promoting activities (McCarthy et al., 1986,  1988a). 
A major RGDS-independent cell adhesion-promoting activ- 
ity was first identified within an A-chain derived, carboxy- 
terminal  33-kD  heparin-binding  fragment  of  fibronectin 
(McCarthy et al.,  1986)  and others have observed similar 
results using a variety of normal and transformed cell types 
(Rogers et al.,  1987;  Mugnai et al.,  1988;  Wayner et al., 
1989). These studies demonstrate that this fragment contains 
two  cell  adhesion-promoting  domains  that  are  localized 
within heparin binding peptide I (McCarthy et al.,  1988a) 
and peptide CS1  (Humphries et al.,  1987).  Although pep- 
tides I and CS1 are both present within the 33-kD fragment 
(McCarthy et al., 1988a), the melanoma cell adhesion-pro- 
moting activity of these two synthetic peptides was shown to 
be distinct.  First,  cell adhesion to either peptide could not 
be cross-inhibited by the other peptide. Also, in contrast to 
peptide I, peptide CS1 failed to bind [3H]heparin in a solid- 
phase binding assay. These results strongly suggest that pep- 
tides I and CS1 interact with distinct cell surface receptors, 
although interaction of both peptides with distinct sites on a 
common receptor cannot be ruled out. 
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Figure  11.  Effect of anti-peptide I IgG on [3H]heparin binding to 
intact fibronectin. Substrata coated with 5 ~g of intact fibronectin 
(m) or 200 #g of BSA (n) were preincubated  for 30 rain in the 
presence of the indicated concentrations of purified anti-peptide I 
antibodies  in  PBS/BSA. Each  well then  received  subsaturating 
amounts  of [3ttlheparin  (~50  ng/weli) and  the  plates  were  in- 
cubated for 2 h at 37°C. The wells were then washed and the amount 
of bound [3Hlheparin was determined.  Each value represents the 
mean of three separate determinations, and the SEM was <10% in 
each case. 
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the requirement (or not) for the peptides to be coupled to a 
larger carrier protein to express the full complement of cell 
adhesion- and spreading promoting activities. Whereas pep- 
tide I was fully active with respect to both criteria regardless 
of whether or not it was coupled, peptide CS1 required cou- 
pling to a larger carder molecule in order to exhibit spread- 
ing activity. Such a requirement for coupling of this peptide 
has been previously noted by Humphries et al. (1986) in the 
original description of this peptide. Despite the requirement 
of coupling for spreading, uncoupled peptide CS1 was active 
at promoting cell adhesion on coated substrata. Whereas this 
difference could indicate the presence of separate adhesion 
and spreading promoting determinants on peptide CS1, which 
is relatively large, it is more likely that the difference repre- 
sents changes in the conformation (and hence specific activ- 
ity) of the peptide that has been bound by the two different 
means. 
The observation that the cell adhesion-promoting activity 
exhibited by peptide I was active within the 33-kD fragment 
of fibronectin was supported by two independent lines of evi- 
dence. First, exogenous peptide I could inhibit cell adhesion 
on the 33-kD fragment of fibronectin although the inhibition 
achieved with this peptide was never complete. Secondly, an- 
tibodies generated against peptide I bound directly to the 33- 
kD fragment of fibronectin (by ELISA) and were effective at 
inhibiting cell adhesion to the 33-kD fragment of fibronectin. 
Whereas these antibodies could virtually eliminate cell adhe- 
sion to peptide I, the inhibitory effects on the 33-kD fragment 
were  never complete,  consistent with the  hypothesis that 
multiple distinct cell adhesion promoting determinants exist 
on the 33-kD fragment. Interestingly, anti-peptide I antibod- 
ies had a limited effect on cell adhesion to intact fibronectin. 
This is consistent with our previous results (McCarthy et al., 
1988a) and the results of others (Woods et al., 1986), which 
demonstrated that antibodies that inhibit cell adhesion to 
heparin binding fragments of fibronectin have a limited effect 
on the level of cell adhesion to intact fibronectin. However, 
such antibodies have  been demonstrated to potentiate the 
effects of exogenous RGD-containing peptides (McCarthy et 
al., 1988a) or to disrupt focal adhesion formation by normal 
fibroblasts (Woods et al.,  1986). 
Anti-peptide I  antibodies,  which  reacted  positively by 
ELISA against intact fibronectin or the  33-kD  fragment, 
were also extremely (60%) effective at inhibiting [3H]hepa- 
rin binding to intact fibronectin, indicating that peptide I 
represents  a  major  heparin  binding  determinant  on  the 
carboxy-terminal heparin binding domain of intact fibronec- 
tin.  The  failure of these antibodies to completely inhibit 
heparin binding to intact fibronectin could relate, in part, to 
the  contribution  of  other  heparin  binding  determinants 
within this region of fibronectin (e.g., peptide II, which was 
not recognized by these antibodies; McCarthy et al., 1988a). 
This  result  further  suggests  that  heparin  binding  to  the 
carboxy-terminal region of fibronectin involves noncontigu- 
ous determinants within this region of the molecule. Multiple 
heparin-binding determinants have previously been proposed 
on other heparin binding proteins such as apolipoprotein B 
and vitronectin (Suzuki et al.,  1985;  Hirose et al.,  1987; 
Cardin et al.,  1989). 
Peptide I  was not as  active on a  molar basis  as  intact 
fibronectin  at  binding  pH]heparin,  requiring  a  100-fold 
molar excess coating concentration compared with that used 
for  fibronectin  in  order  to  achieve  the  same  level  of 
[3H]heparin binding. Despite this difference in absolute ac- 
tivities, a relative comparison of the heparin binding activi- 
ties of peptide I and intact fibronectin showed remarkable 
similarity between these two ligands. The heparin binding 
activities of  these two ligands (and the 33-kD fragment) were 
equally susceptible to the effect of progressively increasing 
salt concentrations (at physiologic levels  or above).  Simi- 
larly, the 50% inhibitory dose of dextran sulfate was much less 
effective (one to two orders of magnitude) than unlabeled 
heparin at inhibiting [3H]heparin binding to either of these 
two ligands. Chondroitin-4 sulfate (CS) was virtually ineffec- 
tive in this regard, even at CS concentrations which were 
four orders of magnitude higher than the level of heparin that 
produced a 50% inhibition. Such specificity has previously 
been observed for heparin binding peptides from laminin 
(Charonis et al., 1988) and type IV collagen (Koliakos et al., 
1989),  although not all heparin-binding ligands show this 
same preference (Koliakos et al., 1989). This suggests, along 
with the antibody data, that the structural features of peptide 
I  that  are  important  for  heparin-binding  activity closely 
resemble those features of this sequence on intact fibronectin. 
That peptide  I-mediated cell adhesion could be  distin- 
guished from peptide CSl-mediated cell adhesion by several 
criteria suggests that the two peptides may mediate cell adhe- 
sion by interacting with distinct cell surface receptors, both 
of which  are  distinct  from the  well  characterized  RGD- 
dependent integrin interaction.  Recent evidence has  been 
presented which demonstrates that anti-B1 integrin antibod- 
ies can inhibit CSl-mediated adhesion of neural crest cells 
or peripheral neurons, indicating that CSl-mediated adhe- 
sion may involve cell surface integrins (Dufour et al., 1988; 
Humphries et al., 1988; Wayner et al., 1989), which are in- 
teracting by an RGD-independent mechanism. By contrast, 
the heparin-binding activity of peptide I argues strongly for 
a role of cell surface proteoglycans/glycosaminoglycans in 
the recognition of the active sequence(s) within this peptide. 
That peptide I promotes cell spreading as well as adhesion 
indicates that the melanoma cell surface receptor for this se- 
quence interacts either directly or indirectly with the cellular 
cytoskeleton of these cells. Cell surface heparan sulfate and 
chondroitin sulfate proteoglycans have been identified with 
properties consistent with a cell surface localization, which 
include an ability to bind to hydrophobic al~inity columns or 
to become  inserted  into liposomes  (Kjell6n et  al.,  1981; 
Woods et al., 1985; Lories et al., 1987; David et al., 1989). 
Putative transmembrane sequences have also been identifed 
on the core proteins of several  proteoglycans (Sant et al., 
1984; Noonan et al., 1988; Saunders et al., 1989), suggest- 
ing that such macromolecules could be involved in peptide 
I-mediated melanoma cell adhesion. It will clearly be of in- 
terest to  use  peptide I  to determine the  role of cell  sur- 
face-associated proteoglycans in mediating melanoma cell 
adhesion to this region of fibronectin. 
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